Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...

Capricor Therapeutics said on Wednesday its cell therapy for a rare muscular disorder met the main goal of a late-stage study, reviving hopes for U.S. approval after a setback and sending its shares ...

Alexander Bryant, 39, was diagnosed with stage four tonsil cancer last December and was recently told it is non-curable, and ...

The DNA inside our cells is constantly being damaged, and one of the worst kinds of damage is a double-strand break—when both ...

Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...

The EMBOLD topline results will be presented at the American Epilepsy Society Annual Meeting at the Georgia World Congress Center, Poster Hall B2, 1.38 from 12:00-2:00 p.m. on Saturday, December 6, ...

Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean ...

BASEL, Switzerland and LINCOLNSHIRE, Il., Dec. 2, 2025 /CNW/ — Vaderis Therapeutics today announced that data from its ...

This peer-reviewed publication marks an important milestone following initial release of study information in August 2024 (see "Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT"). The ...

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial ...